GlassScriptPhysician profile
Alan G Pocinki
NPI 1528151578
$529.03
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $198 · 2021: $73.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $100.74 | 2019-2020 | |
| Abbvie INC. | $71.08 | 2020-2021 | |
| Allergan, INC. | $55.37 | 2019-2020 | |
| Amgen INC. | $51.71 | 2019-2020 | |
| Assertio Therapeutics, INC. | $42.11 | 2019 | |
| Lundbeck LLC | $32.01 | 2020 | |
| Merck Sharp & Dohme LLC | $31.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.47 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.99 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.08 | 2020 | |
| Lilly USA, LLC | $18.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.34 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.66 | 2020 | |
| Biodelivery Sciences International, INC. | $12.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Pocinki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.